124 related articles for article (PubMed ID: 21876406)
1. Personnel exposure in labelling and administration of (177)Lu-DOTA-D-Phe1-Tyr3-octreotide.
Sghedoni R; Grassi E; Fioroni F; Asti M; Piccagli V; Versari A; Iori M
Nucl Med Commun; 2011 Oct; 32(10):947-53. PubMed ID: 21876406
[TBL] [Abstract][Full Text] [Related]
2. Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations.
Grassi E; Sghedoni R; Asti M; Fioroni F; Salvo D; Borasi G
Nucl Med Commun; 2009 Feb; 30(2):176-82. PubMed ID: 19194215
[TBL] [Abstract][Full Text] [Related]
3. Skin dose saving of the staff in 90Y/177Lu peptide receptor radionuclide therapy with the automatic dose dispenser.
Fioroni F; Grassi E; Giorgia C; Sara R; Piccagli V; Filice A; Mostacci D; Versari A; Iori M
Nucl Med Commun; 2016 Oct; 37(10):1046-52. PubMed ID: 27218429
[TBL] [Abstract][Full Text] [Related]
4. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
5. Labelling of
Iori M; Capponi PC; Rubagotti S; Esposizione LR; Seemann J; Pitzschler R; Dreger T; Formisano D; Grassi E; Fioroni F; Versari A; Asti M
Contrast Media Mol Imaging; 2017; 2017():8160134. PubMed ID: 29097938
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW
Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126
[TBL] [Abstract][Full Text] [Related]
7. Beta radiation exposure of staff during and after therapies with 90Y-labelled substances.
Rimpler A; Barth I; Baum RB; Senftleben S; Geworski L
Radiat Prot Dosimetry; 2008; 131(1):73-9. PubMed ID: 18718959
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive dose reconstruction methodology for former rocketdyne/atomics international radiation workers.
Boice JD; Leggett RW; Ellis ED; Wallace PW; Mumma M; Cohen SS; Brill AB; Chadda B; Boecker BB; Yoder RC; Eckerman KF
Health Phys; 2006 May; 90(5):409-30. PubMed ID: 16607174
[TBL] [Abstract][Full Text] [Related]
9. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
10. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
11. Correction factors applied to finger dosimetry: a theoretical assessment of appropriate values for use in handling radiopharmaceuticals.
Sherbini S; Ilas D; Eckerman K; DeCicco J
Health Phys; 2011 Jul; 101(1):1-12. PubMed ID: 21617388
[TBL] [Abstract][Full Text] [Related]
12. Fluoroscopically guided percutaneous vertebroplasty: assessment of radiation doses and implementation of procedural routines to reduce operator exposure.
von Wrangel A; Cederblad A; Rodriguez-Catarino M
Acta Radiol; 2009 Jun; 50(5):490-6. PubMed ID: 19363715
[TBL] [Abstract][Full Text] [Related]
13. Finger doses for staff handling radiopharmaceuticals in nuclear medicine.
Pant GS; Sharma SK; Rath GK
J Nucl Med Technol; 2006 Sep; 34(3):169-73. PubMed ID: 16951286
[TBL] [Abstract][Full Text] [Related]
14. Radiation exposure of the staff at the therapeutic and diagnostic nuclear medicine department. A single centre six years' retrospective study.
Dolezal J
Nuklearmedizin; 2008; 47(4):175-7. PubMed ID: 18690378
[TBL] [Abstract][Full Text] [Related]
15. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
Nayak T; Norenberg J; Anderson T; Atcher R
Cancer Biother Radiopharm; 2005 Feb; 20(1):52-7. PubMed ID: 15778581
[TBL] [Abstract][Full Text] [Related]
16. Exposure of medical personnel to radiation during radionuclide therapy practices.
Lancelot S; Guillet B; Sigrist S; Bourrelly M; Waultier S; Mundler O; Pisano P
Nucl Med Commun; 2008 Apr; 29(4):405-10. PubMed ID: 18317307
[TBL] [Abstract][Full Text] [Related]
17. Radiation exposure assessment of nuclear medicine staff administering [
Riveira-Martin M; Struelens L; Muñoz Iglesias J; Schoonjans W; Tabuenca O; Nogueiras JM; Salvador Gómez FJ; López Medina A
EJNMMI Phys; 2023 Nov; 10(1):70. PubMed ID: 37962683
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of occupational exposure to photon rays in Poland, 2006].
Jankowski J; Kacprzyk J; Tybor-Czerwińska M; Kamiński Z
Med Pr; 2007; 58(4):287-90. PubMed ID: 18041197
[TBL] [Abstract][Full Text] [Related]
19. Semiautomated labelling and fractionation of yttrium-90 and lutetium-177 somatostatin analogues using disposable syringes and vials.
Asti M; Atti G; Iori M; Farioli D; Filice A; Versari A
Nucl Med Commun; 2012 Nov; 33(11):1144-52. PubMed ID: 22889932
[TBL] [Abstract][Full Text] [Related]
20. Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.
Bakker WH; Breeman WA; Kwekkeboom DJ; De Jong LC; Krenning EP
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):265-71. PubMed ID: 17043624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
